Taunia Markvicka

Experienced Pharmaceutical Professional in New York

Taunia Markvicka

Experienced Pharmaceutical Professional in New York

Visit my website

Since early 2016, Taunia Markvicka has served as the Chief Commerical Officer of Symbiomix Therapeutics LLC, a biopharmaceutical company based in Newark, New Jersey, recently acquired by Lupin Pharmaceucticals in October 2017. In this role, she is the primary overseer for commercialization efforts related to the drug Solosec, a first-of-its-kind single oral dose treatment for gynecological infections, that has qualified infectious disease status (QIDP) by the federal government. Taunia Markvicka has been responsible for the commercial strategy, and partner integration since its approval by the FDA. In addition, with her clinical background she has been integral to building the clinical and medical affairs strategic focus, resources, and plans.

Prior to taking her position at Symbiomix Therapeutics, she spent eight years as the senior vice president of commercial strategy and Chief Commercial Officer at Pacira Pharmaceuticals where she lead the acquisition analsysis, building commercial and medical teams and ultimately the launch of EXPAREL, a novel non-opioid for post-surgical pain. After completing her graduate studies in pharmacy and a two-year post-doctoral pharmaceutical fellowship at Rutgers University, Taunia Markvicka went on to earn an MBA from St. Joseph’s University. Outside of her work in the pharmaceutical industry, she enjoys taking in Broadway plays with her family, spending time on the water boating and paddle boarding, and traveling.